CareFirst BlueCross BlueShield Announces Coverage of New Liquid Biopsy Tests for Prostate Cancer
08. Januar 2018 09:58 ET
|
CareFirst BlueCross BlueShield
Baltimore, Md., Jan. 08, 2018 (GLOBE NEWSWIRE) -- CareFirst BlueCross BlueShield (CareFirst), today announced that it has reached a positive coverage decision for the ExoDx® Prostate(IntelliScore)...
CareFirst BlueCross BlueShield and Exosome Diagnostics Announce Evidence Development Collaboration for Molecular Diagnostic Tests
24. August 2017 09:12 ET
|
CareFirst BlueCross BlueShield
Baltimore, Md. and Boston, Ma., Aug. 24, 2017 (GLOBE NEWSWIRE) -- CareFirst BlueCross BlueShield (CareFirst) and Exosome Diagnostics, Inc. (ExoDx) announced today that they have signed an agreement...
American Medical Association (AMA) Grants Exosome Diagnostics a CPT PLA Specific to Its ExoDx® Prostate(IntelliScore) Test
26. April 2017 08:22 ET
|
Exosome Diagnostics
Cambridge, MA, April 26, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that the American Medical Association (AMA) has issued a new CPT® Proprietary Laboratory Analyses (PLA)...